DEVELOPMENT AND VALIDATION OF FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF PARACETAMOL AND TAPENTADOL HYDROCHLORIDE IN TABLET DOSAGE FORM by SHRADDHA J. PARMAR, NAITIK N. CHAMPANERI, SAMIL D. DESAI*, BHAVNA A. PATEL,
AJPRHC                                     Volume 5                              Issue 1                                                            8-15 
 
AJPRHC
 
    Research Article 
DEVELOPMENT AND VALIDATION OF FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC 
METHOD FOR SIMULTANEOUS ESTIMATION OF PARACETAMOL AND TAPENTADOL 
HYDROCHLORIDE IN TABLET DOSAGE FORM 
SAMIL D. DESAI*, BHAVNA A. PATEL, SHRADDHA J. PARMAR, NAITIK N. CHAMPANERI 
For Author affiliations see end of the text 
This paper is available online at www.jprhc.in 
 
 
KEY WORDS: Paracetamol (PCM), Tapentadol HCl (TAP), Spectroscopy, First order Derivative, Validation. 
INTRODUCTION: 
Paracetamol is 4-hydroxy acetanilide. It is analgesic, antipyretic agent and is the active metabolite of 
phenacetin, responsible for its analgesic effect by inhibiting COX 2 enzyme. It is a weak prostaglandin inhibitor 
in peripheral tissues and possesses no significant anti inflammatory effects. It is one of the most important drugs 
used for the treatment of mild to moderate pain when an anti inflammatory effect is not necessary [1-3]. 
Tapentadol Hydrochloride is chemically (3-[(1R, 2R)-3-(3-dimethylamino) -1- ethyl -2- methyl propyl] 
phenol monohydrochloride. Tapentadol is a centrally-acting opioid analgesic is used in the treatment of Acute 
Pain Management. It belongs to Non-Steroidal Anti Inflammatory Drug (NSAIDs). It is a centrally acting 
synthetic analgesic. Although its exact mechanism is unknown, analgesic efficacy is thought to be due to be due 
to ȝ -opioid agonist activity and the inhibition of norepinephrine reuptake. It is also an agonist of the ı2 
receptor, though the function of this orphan receptor remains controversial. The use of PCM and TAP 
combination therapy for the management of the pain associated with Osteoarthritis (OA) has been recommended 
to improve efficacy [4, 5]. 
A Tablet Dosage form containing PCM-325 mg & TAP-50 mg is commercially available. Literature 
survey revealed the most recent methods for determination of Paracetamol like chromatographic, 
electrochemical and spectrophotometric techniques are available [6-13]. Tapentadol Hydrochloride is not official 
in any Pharmacopoeia. Literature review revealed that several analytical techniques for estimation of Tapentadol 
ABSTRACT: 
A simple, precise, accurate and reproducible spectrophotometric method has been developed for 
Simultaneous estimation of Paracetamol and Tapentadol Hydrochloride by employing first order derivative 
zero crossing method in 0.1 N Sodium Hydroxide. The first order derivative absorption at 257.1 nm (zero 
cross point of Paracetamol) was used for quantification of Tapentadol HCl and 289.0 nm (zero cross point of 
Tapentadol HCl) for quantification of Paracetamol. The linearity was established over the concentration 
range of 15-35 ȝg/ml and 3-15 ȝg/ml for Paracetamol and Tapentadol HCl with correlation coefficient (r2) of 
0.9989 and 0.9993 respectively. The mean % recoveries were found to be in the range of 99.52% – 99.88% 
and 98.39% – 98.66% for Paracetamol and Tapentadol HCl, respectively. Interday and intraday studies 
showed repeatability of the method. The method is successfully applied to pharmaceutical formulation, with 
no interference from excipients as indicated by the recovery study. All validation parameters were within the 
acceptable range. The proposed method has been validated as per ICH guideline and successfully applied to 
the simultaneous estimation of Paracetamol (PCM) and Tapentadol HCl (TAP) in their combined Tablet 
dosage form. The proposed method is recommended for routine analysis since it is rapid, simple, accurate 
and also sensitive and specific by no heating and no organic solvents are required. Also use of 0.1 N Sodium 
Hydroxide (NaOH) as a solvent makes it Cost effective and very economical method. 
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Hydrochloride from Various biological Fluids by UPLC, LC/MS/MS, Chiral Chromatography and fluorimetric 
determination are available [14-19].  However,  1st order derivative spectrophotometric method and RP-HPLC [20] 
had been reported, for determination of this combination by using methanol as a solvent. This method uses 0.1 
N NaOH as a solvent which makes method very cost effective as no costly solvent is used. 
                     
(A) Paracetamol    (B) Tapentadol Hydrochloride 
Figure 1: Chemical structure of (A) PCM and (B) TAP 
 
MATERIALS AND METHODS 
 Reagents and chemicals 
Analytically pure Paracetamol and Tapentadol HCl were used. Tablet of Paracetamol and Tapentadol 
HCl in combine dosage form, with a 325 mg PCM and 50 mg TAP label claim, manufactured by Glenmark 
Pharmaceuticals, India were procured from a local pharmacy. 
Instruments 
The Spectrophotometer used for study is Shimadzu UV/Vis 1800 double beam spectrophotometer with 
wavelength accuracy (± 0.3 nm), 1 cm matched quartz cells and UV probe 2.35 software was used for all the 
spectral measurements. Calibrated analytical balance Denver SI234, Germany was used for weighing purpose. 
All statistical calculations were carried out using Microsoft excel 2010 analytical tool. 
Preparation of standard stock solutions 
Accurately weighed 100 mg of PCM and TAP standard were transferred to separate 100 ml volumetric 
flask  and dissolved in  50  ml  0.1  N NaOH.  The flasks  were  shaken;  sonicated  & volume was  made up to  the  
mark with 0.1 N NaOH to give solutions containing 1000 ȝg/ml PCM and 1000 ȝg/ml TAP. 
Selection of Analytical Wavelength 
Solutions of PCM and TAP were prepared in 0.1 N NaOH by appropriate dilution and spectrum was 
recorded between 200-400 nm and all zero order spectrums (D0) were converted to first derivative spectrum 
(D1) using delta lambda 10 and scaling factor 1.0. The overlain first derivative spectrums of PCM and TAP at 
different concentration were recorded. The zero crossing point (ZCP) of PCM was found to be 257.1 nm and 
ZCP of TAP was found to be 289.0 nm (Figure 2). 
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Figure 2: Overlain D1 spectrum of PCM (15-35 ppm) and TAP (3-15 ppm) in 0.1 N NaOH. 
ZCP of PCM (257.1 nm), ZCP of TAP (289.0 nm) 
 
Method validation 
The proposed method has been extensively validated in terms of specificity, linearity, accuracy, 
precision, limits of detection (LOD) and quantification (LOQ), robustness and reproducibility. 
Specificity 
The Drugs were quantified from the taken Pharmaceutical Formulation. The D1 spectrum was recorded 
by appropriate dilutions and the quantities of drugs were determined. 
Linearity 
Appropriate volume of aliquot from PCM and TAP standard stock solution was transferred to 
volumetric flask of 10 ml capacity. The volume was adjusted to the mark with 0.1 N NaOH to give a solution 
containing 15-35 ȝg/ml PCM and 3-15 ȝg/ml TAP. All D1 Spectrum were recorded using above 
spectrophotometric condition. D1 absorbance at 257.1 nm and 289.0 nm were recorded for PCM and TAP 
respectively. Calibration curves were constructed by plotting average absorbance versus concentrations for both 
drugs.  
 
Accuracy 
Accuracy was assessed by determination of the recovery of the method by addition of standard drug to 
the prequantified sample preparation at three different concentration levels 80, 100 and 120%, taking into 
consideration percentage purity of added bulk drug samples. Each concentration was analyzed three times and 
average recoveries were measured. 
Precision 
The intraday and interday precision study of PCM and TAP was carried out by estimating different 
concentrations of PCM (20, 25, 30 ȝg/ml) and TAP (6, 9, 12 ȝg/ml), three times on the same day and on three 
different days and the results are reported in terms of % RSD. 
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Detection limit and Quantitation limit 
ICH guideline describes several approaches to determine the detection and quantitation limits. These 
include visual evaluation, signal-to-noise ratio and the use of standard deviation of the response and the slope of 
the calibration curve. In the present study, the LOD and LOQ were based on the third approach and were 
calculated according to the 3.3ı/S and 10ı/S criterions, respectively; 
Where, ı is the standard deviation of y-intercepts of regression lines and  
 S is the slope of the calibration curve. 
Robustness 
The sample solution was prepared and then analyzed with change in the typical analytical conditions 
like stability of analytical solution. 
Determination of PCM and TAP from combined Tablet dosage form 
Content of Twenty Tablets were weighed accurately. A powder quantity equivalent to 130 mg PCM 
and 20 mg TAP was accurately weighed and transferred to volumetric flask of 200 ml capacity. 100 ml of 0.1 N 
NaOH was transferred to this volumetric flask and sonicated for 15 min. The flask was shaken and volume was 
made up to the mark with 0.1 N NaOH. The above solution was filtered through whatman filter paper (0.45ȝ). 
The solution was diluted with the 0.1 N NaOH to give a solution containing 26 ȝg/ml of PCM and 4 ȝg/ml of 
TAP. The resulting solution was analyzed by proposed method. The quantitation was carried out by keeping 
these values to the straight line equation of calibration curve. 
 
RESULTS & DISCUSSION 
For this method, 289.0 nm (Zero crossing point of TAP) and 257.1 nm (zero crossing point of PCM) of 
first order derivative spectra were selected for the analysis and the linearity range of 15-35 ȝg/ml & 3-15 ȝg/ml 
for PCM and TAP was taken respectively. Straight line equations were obtained from these calibration curves 
which were shown in figure (Figure 3 & 4). The Correlation Coefficients (r2) for PCM & TAP was found to be 
0.9987 & 0.9982 respectively. 
Absorption of PCM at ZCP of TAP & absorption of TAP at ZCP of PCM is taken (Figure 5 & 6). The 
% assay was found to be 99.74% for PCM & 98.54% for TAP respectively (Table 1). No interference was 
observed from the Pharmaceutical excipients. For PCM & TAP the percent recovery found is 99.71 & 98.54% 
respectively (Table 2). The intraday precision and interday precision were expressed in terms of relative 
standard deviation (RSD). For intraday & interday precision % RSD for PCM & TAP was found to be 
satisfactory. The inter day precision at three concentration levels (n = 3) on three different days was also evident 
with a low % RSD providing ruggedness of the method. Hence, the proposed method was evaluated statistically 
and was validated in terms of linearity, accuracy, precision and ruggedness. The present work provides an 
accurate and sensitive method for the analysis of PCM and TAP in bulk and tablet formulation (Table 3). 
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Figure 3: Calibration Curve of Paracetamol 
 
Figure 4: Calibration Curve of Tapentadol HCl 
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Figure 5: Overlain D1 spectrum of PCM (15-35 ppm) in 0.1 N NaOH 
 
 
 
 
Figure 6: Overlain D1 spectrum of TAP (3-15 ppm) in 0.1 N NaOH 
 
Table 1: Results of analysis of tablet formulation 
Drugs Label claim (mg) Amount of drug 
estimated (mg/tab) 
% Label claim ± 
S.D. 
 
% Recovery 
PCM 325 324.36 99.80 ± 0.000169 99.76% 
TAP 50 49.56 99.12 ± 0.000039 98.90% 
 
Table 2: Results of recovery studies (tablet) 
% 
Level 
Amt. of 
PCM 
taken in 
ȝg/ml 
Amt. of 
TAP 
taken in 
ȝg/ml 
Amt. of 
Std 
PCM 
added in 
ȝg/ml 
Amt.of 
Std TAP 
added in 
ȝg/ml 
% 
Recovery 
(PCM) 
% 
Recovery 
(TAP) 
%RSD 
PCM 
%RSD 
TAP 
80% 26 4.0 20.8 3.2 99.68% 98.86% 0.92% 1.04% 
100% 26 4.0 26.0 4.0 99.85% 99.14% 1.04% 1.12% 
120% 26 4.0 31.2 4.8 99.76% 98.69% 0.89% 0.96% 
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Table 3: Results of validation parameters 
Parameter Paracetamol Tapentadol HCl 
Linearity (ȝg/ml) 15 – 35 ȝg/ml 3 – 15 ȝg/ml 
Co-relation coefficient(r2) 0.9989 0.9993 
Slope 0.0012 0.0007 
Intercept 0.0005 0.0004 
LOD (ȝg/ml) 1.16116 0.18257 
LOQ (ȝg/ml) 3.51868 0.55325 
         Precision 
Intraday (n=3) Mean ± %RSD 99.74 ± 1.14 99.18 ± 0.93 
Interday (n=3) Mean ± % RSD 99.58 ± 1.02 98.86 ± 1.24 
 
CONCLUSION 
Based on the results obtained, it is found that the proposed method is accurate, reproducible & 
economical and can be employed for routine quality control of Paracetamol and Tapentadol HCl in bulk and its 
dosage form. 
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